BN Business News
Add your company to Business Communicator →

Business · 27/12/2011Updated: 10/17/2026 · 1 min read

National Institutes of Health to Grant Exclusive License for Cardiac Disease Treatment

Summary

The National Institutes of Health is considering granting a worldwide exclusive license to practice methanocarba analogues of purine and pyrimidine nucleosides and nucleotides to treat or prevent cardiac diseases in humans, based on patents filed in 2000 and 2001.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →